ArticleRedox biology2026
XRCC1 deficiency drives telomeric chromatin leakage, inflammatory signalling and senescence.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-trapping scaffold protein: significance in cancer cell innate immune signaling and opportunities for immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome integrity is constantly challenged by oxidative DNA damage, which, if left unrepaired, can result in replication stress, chromosomal instability, and tumorigenesis. The base excision repair (BER) pathway is essential for resolving oxidative base lesions such as 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG). Among BER factors, APE1 and XRCC1 play critical roles not only in lesion repair but also in maintaining replication fork stability. Here, we investigate the cellular consequences of APE1 and XRCC1 deficiency in isogenic breast epithelial models (MCF10A and MCF7), under basal and oxidative stress conditions to better dissect the mechanisms through which these factors safeguard genome integrity. We show that XRCC1 deficiency, more than APE1 depletion, leads to an increase of the DNA damage signalling, and the formation of cytoplasmic chromatin fragments (CCFs) containing telomeric DNA. XRCC1-deficient cells also exhibit activation of the cGAS-STING pathway, inflammatory signalling, and senescence phenotypes. Our findings identify XRCC1 as a central suppressor of oxidative stress-induced cytosolic DNA accumulation and immune signalling. These results suggest that targeting XRCC1 may offer a therapeutic avenue to trigger tumour senescence and promote anti-tumour immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.